Bend Therapeutics' Onvansertib shows promise in clinical trials for cancer treatment.

The article discusses the financial and clinical performance of a company, with a focus on the potential of a drug candidate called Onvansertib. The drug has shown promise in clinical trials for treating various types of cancer. The company is anticipating positive results from further trials, which could lead to regulatory approval and commercialization of the drug. The article highlights the risks and uncertainties associated with the drug development process, but also notes the potential for significant returns for investors if the drug is successful.